

Index

a

6 Å Rule 243–245
 – demonstration 244
 – limitations 245
 – prediction of binding poses 247–249
 – prediction of SoM 244, 245
 – – methodological approaches 245–247
 – protein flexibility 249–253
 – validity 245
 abacavir 406
 absolute reasoning domain 307–310
 – relative confidence levels 309
 absorption, distribution, metabolism, and excretion/and toxicity (ADME/ADMET) 40, 43, 60, 325, 327, 367, 441
 – ADMET Predictor 42, 47, 65, 70
 – ADMEWORKS Predictor 48
 – data on most FDA-approved drugs 64
 – measurements 321
 – physiological ADMET data for approved drugs 62
 – QikProp, software module for predicting 39
 acceptor capability 379, 382
N-acetyltransferases (NATs) 29, 402, 444
 activation energy 151, 266, 267, 271
 ADRs, *see* adverse drug reactions (ADRs)
 adverse drug reactions (ADRs) 7, 58, 59, 337, 403, 404
 – caused by reactive metabolites 8
 – off-target 8
 – on-target 7
 aglycones 420, 421
 AhR/ARNT signaling transduction pathway 466
 AhR-inducible gene battery 461
 ALCHEM 299
 alcohol consumption 443, 460
 aldosterone synthase 118, 363

algorithms

– Algorithm Builder (Pharma Algorithms) 379
 – Bayesian classification algorithms 339
 – docking algorithm 246
 – genetic algorithm *k*-nearest neighbor (GA-kNN) 388
 – SMART-Cyp's SoM algorithm 67
 amine 299
 – acetylation reactions 400
 – E-state index 384
 – rule about demethylation of 299
 ANOVA (analysis of variance) 325, 326
 antioxidants 421
 antiretrovirals 441
 aprepitant 405
 area under the curve (AUC) ratios 280, 352, 452, 473, 476
 aromatic/aliphatic hydroxylation 42
 artemisinin 405
 artificial intelligence 19
 artificial neural network models 334
 aryl hydrocarbon receptor (AhR) 364, 460
 aryl hydrocarbon receptor nuclear translocator (ARNT) 460, 466
 atorvastatin 189
 ATP hydrolysis 374, 376
 AutoDock Vina software 31, 40, 285
 autooxidation 9
 AZD5438 494
 azole compounds, PXR antagonist model based on 365

b

basic-helix-loop-helix (bHLH) protein 460
 Bayesian classifiers 334
 BEH C₁₈ column 494
 Bennett acceptance ratio (BAR) 185

- benzodiazepines 6
 - benzphetamine 190
 - B-factors 179
 - 1 β -hydroxytestosterone 203, 204, 207
 - space-filling model 207
 - bile acid esters 11
 - bile salt export pump (BSEP) 374
 - bioactivation 7, 406
 - bioactivity-based mechanistic models 403
 - bioactivity-mediated toxic compounds
 - rationalization of 404
 - bioavailability (*F*) 226
 - biological oxygen demand (BOD) 301
 - biological system 3
 - used in drug metabolism investigations, classification 13
 - biotransformations 3, 10, 29, 41, 44, 237, 299, 301, 422
 - black box models 323
 - blood–brain barrier 70, 374
 - bomb calorimetry 463
 - bootstrap aggregation 380
 - breast cancer resistance protein (BCRP) 374, 375, 427
 - bupropion 474
- c**
- calcium channel blocker 106, 110, 441
 - calculated molar refractivity (CMR) 379, 382, 383
 - Cambridge Crystallographic Database (CSD) 225
 - capillary electrophoresis (CE) 486
 - catechol-*O*-methyltransferase (COMT) 363
 - Caucasian hepatoblastoma 427
 - cell-based assays 465
 - cetirizine 6
 - chemical ionization (CI) 487
 - chemical transformations 64, 182, 183, 407
 - achieved by CYPs 134
 - 5-chloro-1,3-benzodioxol-4-amine
 - positive ion mass spectrum 489
 - chloroperoxidase (CPO) 135
 - cholesterol esters 11
 - chorismate mutase 192
 - circular dichroism (CD) 206
 - cisplatin 7
 - classification and regression trees (CART) 325
 - comparative molecular field analysis (CoMFA) 326
 - comparative molecular similarity indices analysis (CoMSIA) 326
 - comprehensive expert software packages 16
 - computer prediction models
 - from multiple sources 310–312
 - confusion matrix 386
 - conjugation reactions 10, 29, 205, 398, 400
 - constitutive androstane receptor (CAR) 336, 402, 460
 - pharmacophore model 366
 - cyclohexyl ring, oxidation 297
 - cyclosporine 87, 106, 122, 378, 441
 - CYP1A2
 - expression 471
 - inhibition, flavonoid derivatives 333
 - isoform 335
 - ligands 355
 - CYP3A
 - enzyme family 400
 - pregnane X receptor (PXR) 404
 - CYP3A4
 - activity 443, 468
 - chronic alcohol consumption 460
 - diabetes 460
 - fasting 460
 - GRID MIFs of 224
 - inhibition
 - – models 334, 360
 - – quantitative pharmacophore models 360
 - inhibitor (*see* ritonavir)
 - isoforms, classification model 335
 - MD simulations 164
 - mechanism-based inhibitor of 459
 - structure 189
 - substrate
 - – models 364
 - CYP3A5 354, 360, 473
 - primary enzyme expressed in 422
 - CYP1A2 CoMFA model 336
 - CYP assays
 - experimental errors for 323
 - high-throughput screening assays 328
 - CYP2B6 474
 - crystal structure 356
 - substrates model 355
 - CYP2C9 40, 43, 47, 78, 86, 92, 93, 95, 123, 249, 329, 354, 357, 457, 469
 - activity 406
 - heteroactivation model 363
 - inhibitors 332, 336, 356, 363
 - – pharmacophore models 356
 - ligands 356, 363, 364
 - substrates
 - – pharmacophore model 357

- CYP2C19 83, 126, 329, 333, 334, 358, 444
 - inhibitor pharmacophore model 358
 - inhibitors 358
- CYP2D6
 - activity 92, 93, 112, 244, 256, 333, 335, 406, 442
 - inhibition models 334
 - isoforms
 - classification model 335
 - pharmacophore model 358
 - quantitative model 359
 - CYP-electron transfer protein interactions 81, 82
- CYP from a GRID perspective 224–226
- CYP inhibition 126, 128, 234, 236, 266, 323, 325, 332, 447
 - assays 323
- CYP isoforms 32, 33, 35, 36, 111, 189, 281, 321, 329, 334, 358, 431, 434, 473
- CYP-mediated site of metabolism prediction
 - applications to SoM prediction 280, 281
 - isoform-specific models 281–283
 - isoform-unspecific models 283, 284
 - combinations of structure-based models and reactivity 284, 285
 - machine learning methods applied to 278
 - atomic descriptors 278, 279
 - machine learning methods and optimization criteria 279, 280
 - reactivity-based methods applied to 274
 - comprehensive methods 276–278
 - methods only applicable to carbon atoms 274–276
- CYP polymorphism 64, 323
- CypScore software 41
- CYP model-based prediction, FDA guidance 452
- cysteine 496
- cytochrome P450 (CYP) enzymes 10, 16, 29, 77, 103, 199, 492. *See also various isoforms*
 - analysis methods 204
 - circular dichroism (CD) 206
 - HPLC–UV 204, 205
 - LC–HRMS 205
 - LC–MS 205
 - LC–MS/MS 205
 - NMR 205–207
 - X-ray diffraction 206
 - binding site of isoforms 117
 - complex CYP products 208–210
 - docking for predicting kinetic parameters 120
 - challenges 120
 - human CYPs classification based on major substrate class 200
 - inhibition 321
 - assays 491, 492
 - issues in predictions 213, 214
 - K_m and k_{cat} values
 - Michaelis–Menten interpretation 125
 - and relationship with substrate and protein structure 124–127
 - for various substrate–isoform combinations 121–123
 - known substrates of various human CYP isoforms 105, 106
 - methods for analysis of products of drugs 203, 204
 - molecular dynamics studies 89–91
 - number of CYPs present in various species 107
 - pathways 400
 - protein–ligand crystal structures 119, 120
 - SAR of reaction rates 213
 - structural data 199
 - structural insight into substrate recognition by 107, 108
 - CYP2A6 108, 109
 - CYP2A13 109, 110
 - CYP3A4 115
 - CYP8A1 115, 116
 - CYP11A1 116–118
 - CYP19A1 118, 119
 - CYP46A1 119
 - CYP1A1, CYP1A2, and CYP1B1 108
 - CYP11B2 118
 - CYP2C8 110–112
 - CYP2C9 112
 - CYP2D6 112, 113
 - CYP2E1 113
 - CYP2R1 113–115
 - structure–activity relationships based on products 210, 211
 - knowledge-based SAR 212
 - SARs based on chemical bond energy 211
 - SARs based on docking 211, 212
 - structure-based approaches to study metabolism of substrates by 243
 - 6 Å Rule 243–245
 - substrate binding 199
 - substrate identity in various species 104, 106, 107
 - substrate properties for various human isoforms 120, 123, 124

- substrate recognition in catalytic cycle 103, 104
 - systems for production of reaction products and analysis of systems 200
 - – membranes from heterologous expression systems 202, 203
 - – purified CYPs in reconstituted systems 201, 202
 - – tissue microsomal systems 201
 - – *in vivo* systems 201
 - untargeted searches for CYP reactions 208
 - cytosolic enzyme systems 428
- d**
- databases 11
 - Cambridge Crystallographic Database (CSD) 225
 - Human Metabolome Database (HMDB) 59
 - data mining and machine learning approaches 41, 42
 - disadvantage of mining approach 41
 - FAsT MEtabolizer (FAME) 42
 - Metaprint2D 41
 - P450 Regioselectivity module of Percepta 42
 - RegioSelectivity (RS)-WebPredictor 42
 - dealkylation 29
 - deglycosylation 29
 - dehydrogenases 17
 - demethylation 299
 - density functional theory (DFT) 134
 - desloratadine 6
 - detoxification 3, 9, 133, 321, 418, 421, 423
 - diazepam 7
 - diclofenac 86
 - dietary component
 - bioavailability/elimination, flow chart 417
 - dietary tyramines
 - degradation of 362
 - dihydrotestosterone
 - multistep pathway of oxidation, catalyzed by CYP19A1 210
 - sites of oxidation by CYP3A4 212
 - dimethyl sulfoxide (DMSO)
 - concentrations 447
 - dioleoylphosphatidylcholine (DOPC) 96
 - DME system 436
 - docking 39, 40
 - AutoDock 40
 - AutoDock Vina 40
 - Glide 40
 - GOLD 40
 - IDSite 40
 - software packages for 40
 - donor capability 379
 - dopamine
 - mechanism of formation 160–163
 - 3D-QSAR modeling 15
 - DrugBank 57, 58
 - capecitabine drug metabolism pathway 58
 - drug-drug interaction (DDI) 12, 64, 70, 323, 441
 - additional factors influencing drug metabolism 442, 443
 - drug metabolism enzymes, *in vitro* models 463–474
 - drug metabolism, inhibition of 441
 - metabolic 441
 - metabolism, transcriptional regulation 460–463
 - pharmacokinetics (PKs) 441
 - primary hepatocyte culture models 459
 - drug–food interactions 64, 70
 - drug metabolism enzymes
 - drug’s clearance 441
 - drug metabolism enzymes, *in vitro* models
 - cellular models, gene expression 471–474
 - control/test compounds, treatment 470, 471
 - gene reporter assays 465, 466
 - induction assays, in cellular models 468–470
 - induction studies, cellular models for 466–468
 - ligand binding assays 463–465
 - drug metabolism, factors affecting 12
 - epigenetic mechanisms 13
 - intra-individual factors 13
 - pharmacodynamic/pharmacokinetic drug responses 12
 - drug metabolism, inhibition of 441
 - cytosol 456, 457
 - human liver microsomes (HLMs) 445–456
 - predicting inhibition, *in vitro* models 444, 445
 - primary hepatocytes 458, 459
 - recombinant enzymes 457, 458
 - S9 fraction 456, 457
 - drug metabolism, pharmacokinetics (DMPK) 321
 - drug-metabolizing enzymes, *in vitro* inducers 470
 - drug’s fate in body 5
 - dynamics of CYPs 88

- active site access and egress pathways 93–95
- active site flexibility 88, 92, 93
- active site solvation 93

e

- EC₅₀ values 324, 434, 464, 465, 473
- efflux ratio (ER) 377, 378
- electron impact (EI) 487
- electrophiles 8
- electrophoresis-based separation 486
- electrospray ionization (ESI) 487
- electrostatic effect 163
- encainide 7
- encoding rules in a knowledge base 299
- endoplasmic reticulum (ER) 423
- endoxifen 7
- endpoint methods 186
 - linear interaction energy 187
 - molecular mechanics-generalized Born surface area (MM-GBSA) 186, 187
 - QM endpoint methods 187
- epoxidation 113, 133, 209, 266, 283
 - aromatic and double bonded carbon atoms 271, 272
- ergodic hypothesis 181
- estradiol 10, 105, 106
- estrone 10, 11
- experimental drug metabolism 18
- expert software packages 11
- exponential averaging (EXP) 185

f

- fadrozole 118
- Fa2N-4 cell line 466
- FAst MEtabolizer (FAME) 42
- fatty acids 77
- felodipine 106, 110, 441
- feofenadine 106, 444
- flavin-containing monooxygenases 17, 444
 - catalyzed *N*-oxygenation of tertiary amines 10
- flavonols
 - glucuronidation of 361
 - UGT1A9 pharmacophore model 361, 362
- flurbiprofen 43
 - ligands 357
- food bioactives
 - bioavailability (BA) 416
 - first-pass metabolism 418
 - intestinal absorption 416–418
 - metabolism, *in vitro* models classification 418, 419

- Fourier transform ion cyclotron resonance (FT-ICR) instruments 487
- free energy cycle 184
- free energy methods 183
 - endpoint methods 186
 - linear interaction energy 187
 - molecular mechanics-generalized born surface area 186, 187
 - QM endpoint methods 187
 - pathway methods 183, 184
 - Bennett acceptance ratio 185
 - free energy perturbation 185
 - pathway planning 184, 185
 - thermodynamic integration 185, 186
- free energy perturbation 185
- free radicals 9
- FuFo actives
 - bioavailability 415
 - high concentrations 422
 - ingredients 415
 - pharmacokinetics (PK) of 415
- functional proteins 4, 12, 13, 16

g

- GALAS modeling approach 42
- gas chromatography (GC) 204, 486
- gas chromatography–mass spectrometry (GC–MS) 302
- gene expression 12
- GeneGo pathway 405
- gene products 12
 - regulatory 12
- genetic algorithm *k*-nearest neighbor (GA-kNN) 388
- genetic polymorphisms 13
- Gibbs energy 182
- Gilbert's syndrome 442
- GIT enzymes 416
- Glide software 40
- glucuronidation 6, 9, 10, 29, 295, 337, 354, 361, 362, 422, 442, 443, 493
- glutathione (GSH) 9, 496
 - hepatic 400
 - trapping 235
- glutathione *S*-transferases 9, 17, 29, 422
- glycosylated flavonoids 421
- GOLD software 31, 40, 248, 254
- graphical processing unit (GPU) technologies 179
- GRID/GOLPE QSAR methodology 337
- GRID software 223
- gut microflora
 - complex intestinal models (TIM-2) 421

- exposure time 419
- fecal slurry 421
- isolated pure bacterial cultures 421
- modifications 419
- several microbial enzymes 420
- *in vitro* models 420, 421
- gut wall
 - clearance 422
 - metabolism (*see* intestinal metabolism)
 - physiological illustration depicting 416

h

- HepaRG cell culture model 467, 468, 471
- hepatic clearance 423
- hepatic enzyme leakage 471
- hepatic metabolism
 - cryopreserved hepatocytes *vs.* microsomes 428, 429
 - FuFo ingredients, pharmacokinetics 423
 - hepatocyte cell lines 426, 427
 - hepatocytes, in culture 429–431
 - microsomes 424
 - physiological illustration depicting 416
 - primary cultures 427, 428
 - S9 fractions 426
 - supersomes 424
 - *in vitro* liver metabolism models
 - – advantages/disadvantages of 425, 426
 - *in vitro* models 424
- hepatocyte nuclear factor 4 α 353
- hepatocytes 11, 13, 373, 423, 427–429, 433, 445, 446, 458, 463, 468, 470, 475, 491
- hERG potassium channel 404
- heterologous expression systems 202
 - membranes from 202
 - – insect cell systems 202
 - – mammalian cells 202
 - – microbial membrane systems 202, 203
- heteronuclear multiple bond correlation (HMBC) 206
- heteronuclear single quantum coherence (HSQC) 206
- high-performance computing (HPC) facilities 180
- high-performance liquid chromatography (HPLC) 203, 204, 434
- high-resolution mass spectrometry (HRMS) 205
- human CYPs 78
 - based on major substrate class 200
 - genes encoding 77
 - structural features 78–81
 - three-dimensional structures 78

- human endogenous steroid biosynthesis 363
- human ether-a-go-go-related gene (hERG) 321
- human hepatoma cell line HepG2 465
- human liver microsomal stability
 - QSAR models of 339
- human liver microsomes (HLMs) 445–456
 - CYP inhibitors 449
 - direct inhibition 447–452
 - liver S9 fractions 456, 458
 - time-dependent inhibition 452–456
 - time-dependent inhibition experimental design 454
 - *in vitro* to *in vivo* extrapolation (IV/IVE) 449
- Human Metabolome Database (HMDB) 59
- human organic cation transporter 1 (hOCT1) 375
- hydrogen bonding 85, 110, 134, 151, 224, 249, 382, 391
 - capacity 385
- hydrolases 16, 17
- 3-hydroxylated benzodiazepines 6
- hydroxylation 29
 - of aliphatic carbon atoms 268
 - aromatic and double bonded carbon atoms 271, 272
- hydroxymethylbenzene 293
- 4-hydroxytamoxifen 7, 405

i

- ibuprofen 11, 86
- IC₅₀ inhibition study design 450
- IC₅₀ values 434
- idiosyncratic drug reactions (IDRs) 8
- IDSite 40
- indomethacin 86
- inducer models 363
 - hetero/autoactivation 363
 - – CYP3A4 substrate model 364
 - – CYP2C9 heteroactivation model 363, 364
 - nuclear receptors 364
 - – CAR ligands 366
 - – pregnane X receptor 364–366
- inhibition assays 329
- inhibitor concentrations (IC₅₀) curve 447
- interactions with metabolizing enzymes
 - methods for predicting 31–36
- inter-individual factors 12
- intestinal metabolism 421
 - FuFo actives 422
 - subcellular/cellular models 423

- tissue intact models 423
- *in vitro* models 422, 423
- in vitro* hepatocyte variation. 430
- in vitro* liver metabolism models
 - advantages and disadvantages of 425, 426
- in vitro* metabolism models
 - mathematical models for 432, 433
 - measurement methodology 432
 - pharmacokinetic analysis 431, 432
- isothermal titration calorimetry (ITC) 180

k

- KBS, *see* knowledge-based system (KBS)
- ketoconazole 462, 463
- kinetic isotope effects (KIEs) 213, 214
- knowledge-based application 299
- knowledge-based software 16, 37–39
- knowledge-based system (KBS) 37–39, 44, 45, 293, 313, 407
 - absolute and relative reasoning 307–310
 - basic structure of 294
 - building/maintaining 295–299
 - encoding rules 299, 300
 - logic of argumentation 303–307
 - MYCIN 295
 - performance, validation/assessment of 312–314
 - predictions from multiple sources 310–312
 - ways of working 301, 302
- Kupffer cells 445

l

- lactase phlorizin hydrolase (LPH) 421
- L-742 694 compound 405
- lead optimization 226
 - challenges 226
- leave-many-out (LMO) 326
- leave-one-out (LOO) 326
- level of quantification (LOQ) 434
- libraries 53, 447
 - precalculated fragment-based 37
- ligand-based approach 30, 48, 351, 355
- ligand binding assays 463–465
- ligand-derived models 37
- ligand parameterization 188, 189
- ligand–protein interactions 223, 225, 248
- linear interaction energy (LIE) 247
- linking experiment and simulation 180
- lipid peroxidation 9, 10
- lipophilic
 - anionic substrates 86, 95, 97
 - drugs 8
 - interactions 79

- metabolites 11
- xenobiotics 353
- liquid chromatography–mass spectrometry (LC–MS) 302
- liquid chromatography–mass spectroscopy/mass spectroscopy (LC–MS/MS) 447
 - direct inhibition experimental scheme 448
- liver
 - clearance parameter (CL_{Hl}) 431
 - cytosol 457
 - microsomes 339
 - toxicity 496
 - *in vitro* cellular models 446
- logic of argumentation, usage 303–307
- loratadine 6
- lorazepam 6
- luciferase 464–466

m

- machine learning approaches 41, 42
- major histocompatibility complex (MHC) 406
- MassMetaSite 236–239
- mass spectrometry (MS) 485
- Matthews correlation coefficient (MCC) 327, 334, 387
- Maximum Unbiased Validation (MUV) database 352
- McGowans characteristic volume 382
- MD simulations 247, 248
 - CYPs in lipid bilayers 96
- MetabolExpert software 15, 16, 301
- metabolic
 - enzymes, phase I 362, 363
 - intermediate complex 360
 - profiling, toxicological effects 353
 - stability 491, 492
 - toxification 7
 - – mechanisms of toxicity, parameters 437
- metabolism
 - transcriptional regulation
 - – gene induction pathways 460–462
 - – gene repression/suppression 462, 463
- Metabolite Database 41
- metabolite detection/profiling 485–496
 - chromatography 486, 487
 - cytochrome P450 inhibition assays 491, 492
 - liquid chromatography–mass spectrometry 487–490
 - metabolic stability 491, 492
 - reactive metabolite detection 496

- sample preparation for 490, 491
 - sample preparation for LC–MS 490, 491
 - *in vivo/in vitro* studies, identification 492–495
 - metabolite identification (MetID) 224
 - metabolites
 - classification of drugs without/with active 7
 - detection and profiling (*see* metabolite detection/profiling)
 - discrepancy between numbers of observed and possible metabolites 298
 - formation
 - vs. substrate depletion 432
 - major determinants of metabolite formation 267
 - metabolite predictors 66
 - methods for predicting SoMs, structures of 31–36
 - online databases 55
 - predicting toxic effects (*see* predicting toxic metabolites)
 - software for predicting (*see* software for predicting metabolites)
 - spectroscopy 206–208
 - structure prediction 30
 - methods for 31–36
 - of toluene (methylbenzene) 293
 - Metabolizer 45, 65, 297
 - MetaPred server 68
 - MetaPrint2D 41, 66, 67, 68
 - MetaPrint2D-React 66, 401
 - MetaSite software 15, 16, 39, 226, 227
 - accessibility function 227–229
 - automated metabolite identification (*see* MassMetaSite)
 - prediction for PH-302 CYP3A4 inhibition 237
 - prediction of CYP inhibition 234–236
 - reactivity function 229, 230
 - site of metabolism prediction 230, 231
 - validation 231
 - META software 15, 16, 44
 - METEOR software 15, 16, 302
 - 3-methoxy-*O*-desmethyl encainide 7
 - 2-methyl-3-(3,5-diiodo-4-hydroxybenzoyl) benzofuran 356
 - 4-methyl(hydroxymethyl)benzene 293
 - MEXAlert software 39
 - Michaelis–Menten constant 424, 431
 - micronutrients 415
 - midazolam 474
 - MIF-based SoM predictor 46
 - MIF-based technologies 224
 - MIF discretization 227
 - MIFs, *see* molecular interaction fields (MIFs)
 - molecular docking 69. *See also* docking
 - molecular dynamics (MD) 78, 179
 - simulations 37
 - molecular interaction fields (MIFs) 39, 46, 223
 - molecular orbital (MO) methods 16
 - monoamine oxidase (MAO) 362
 - morphine 7
 - morphine 6-*O*-glucuronide 7
 - multidrug resistance (MDR) 374, 375, 378
 - multidrug resistance–associated proteins 374
 - multiple linear regression (MLR) 323
 - CYP2C9 substrates 329
 - mutations 78, 86, 91, 256
 - analysis of CYP2B4 82
 - CYP1A2 T124S 85
 - CYP2D6 F483A 192
 - effect of 256–258
 - predicting substrate formation and 258
- n**
- N*-acetyltransferases (NATs) 29
 - NADPH-regenerating system 447
 - naproxen 85, 86, 105
 - negative predictive value (NPV) 386
 - Netherlands Cancer Institute (NKI) 378
 - nicotinamide adenine dinucleotide phosphate oxidase 445
 - NMR relaxation 179
 - N/O-dealkylation 42
 - non-CYP oxidoreductases 16
 - nordazepam 7, 60
 - nuclear magnetic resonance (NMR) spectroscopy 248, 486
 - nuclear overhauser correlated spectroscopy (NOESY) spectra 206
 - nuclear receptors (NRs) 353
 - CYP induction 353
 - nucleophiles 8
- o**
- O*-desmethyl encainide 7
 - O*-desmethyltramadol 7, 60
 - omeprazole 358
 - online drug metabolism databases 53, 54, 56, 57
 - categories 56
 - DrugBank database 57, 58
 - Human Metabolome Database 59
 - PharmGKB 59, 60

- PubChem 61
 - specialized databases 63
 - PK/DB 64
 - PKKB 64
 - SuperCYP 64
 - UM-BBD 63
 - synoptic databases 61
 - BindingDB 63
 - ChEBI 62
 - ChEMBL 62
 - KEGG 62, 63
 - Wikipedia 60, 61
 - online drug metabolism prediction servers 65
 - ADMET predictors 70
 - metabolite predictors 66
 - SoM predictors 66–68
 - specialized predictors 68–70
 - oral contraceptives 441
 - organic anion transporters (OATs) 374, 427
 - organic anion transporting polypeptides (OATPs) 427
 - organic cation transporters (OCTs) 373, 427
 - oxazepam 6, 7
 - oxidative hydroxylation 299
 - oxidative stress 8, 9
 - oxidoreductases 8, 9, 16
- P**
- 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 94, 96
 - paracetamol 6, 400, 407
 - parameterization
 - ligand 188
 - linear interaction energy 187
 - partial least-squares discriminant analysis (PLS-DA) 332
 - PASS (prediction of the activity spectra of substances) 403
 - pathways-based information 404
 - PBPK models 452
 - Percepta module 42
 - peroxidases 9, 17
 - P-glycoprotein (P-gp) 418, 427
 - P-gp Predictor 69
 - pharmacodynamic (PD) effects 5
 - Pharmacogenomics Knowledge Base (PharmGKB) 59
 - pharmacokinetic (PK) effects 5
 - pharmacokinetic–pharmacodynamic (PKPD) modeling 5
 - pharmacophore-based methods
 - CYP induction, nuclear receptors 353
 - definitions of 352
 - determination of chemical features 354
 - inducer models 363–366
 - qualitative models 352
 - substrate and inhibitor 354–363
 - pharmacophore models 15, 284, 340, 352, 353
 - substrate and inhibitor 354–363
 - phase space 181
 - phenacetin 6, 474
 - phenobarbital 462
 - N*-(1-phenylcyclohexyl)-2-ethoxyethanamine 296
 - 3'-phosphoadenosine-5'-phosphosulfate (PAPS) 338
 - phosphoglycoprotein (P-gp)-mediated disposition 6, 373, 374
 - adenosine triphosphate (ATP) 374
 - ATPase binding cassette (ABC) 373
 - compound structure, influence 380–385
 - cytochrome P450 3A4 (CYP3A4) 375
 - drug discovery, application 388–391
 - drug transporter 374
 - QSAR models (*see* QSAR models)
 - QSAR prediction 376
 - solute carrier (SLC) superfamilies 373
 - substrate identification 389
 - *in vitro/in silico* approaches 374
 - physiologically based pharmacokinetics (PBPK) 392, 451, 452
 - pioglitazone 235
 - GSH adducts 235
 - inhibition for CYP isoforms 235, 236
 - polymorphisms 17, 77
 - polyunsaturated fatty acids 9
 - positive predictive value (PPV) 386
 - potential energy surface (PES) 183
 - PreADMET 70
 - predicting toxic metabolites 397, 401
 - absolute metabolism likelihoods and rates 401, 402
 - anticipating toxic effects of 398
 - bioactivity-based mechanistic models 403, 404
 - CYPs, polymorphisms 402
 - cytochrome P450 (CYP) pathways 400
 - endogenous/exogenous substances 397
 - hepatic glutathione (GSH) 400
 - incorporating pathway information 404–406
 - knowledge-based systems 407
 - MetaPrint2D-React 401
 - pharmacogenetic data 402

- political developments 408
 - reactive metabolites 407, 408
 - relative and absolute rates 399, 401, 402
 - *in silico* methods 397
 - toxic effects 402
 - bioactivity-based mechanistic models 402, 403
 - incorporating pathway information 404–406
 - knowledge-based systems 407
 - reactive metabolites 407, 408
 - toxicogenetic/pharmacogenomic approaches 406, 407
 - toxicogenetic/pharmacogenomic approaches 406, 407
 - UDP-glucuronosyltransferases (UGTs) 402
 - workflow for 399
 - P450 regioselectivity module of percepts 42
 - pregnane X receptor (PXR) 336, 364, 402, 427, 460
 - procarcinogens 77
 - prodrugs 6, 7
 - propranolol 493
 - prostaglandins 77, 115
 - Protein Data Bank (PDB) 225, 355
 - protein flexibility 249–253
 - protein–ligand complexes 37, 107, 354
 - protein–ligand crystal structures 119, 120
 - protein–ligand interactions 39
 - PubChem 61
 - purified CYPs in reconstituted systems 201, 202
 - pyrazoles 294
- q**
- QikProp software 39
 - QM/MM studies 135
 - applications to cytochrome P450 enzymes 144–146
 - conversion of Cpd 0 into Cpd I in T252X mutants 148–151
 - Cpd I species of different cytochrome P450s 154, 155
 - formation of Cpd I from Cpd 0 146–148
 - mechanism of cytochrome P450 StaP 155–160
 - mechanism of dopamine formation 160–163
 - properties of Cpd I 151–154
 - methodological issues in studies 136
 - electrostatic QM/MM interactions 139
 - MM methods 138
 - QM methods 137, 138
 - QM/MM boundary treatments 139, 140
 - QM/MM energy *versus* free energy calculations 141
 - QM/MM geometry optimization 140
 - QM/MM molecular dynamics and free energy calculations 140, 141
 - QM/MM partitioning 136, 137
 - subtractive *versus* additive QM/MM schemes 139
 - practical issues in studies 141
 - accuracy of QM/MM results 143
 - extracting insights from QM/MM calculations 144
 - QM/MM geometry optimization 143, 144
 - QM/MM setup 142, 143
 - QM/MM software 141, 142
 - QSAR models 322, 353, 375, 405
 - applicability domains 328
 - assessment and validation 327, 328
 - black box models 323
 - classical 326, 329–333
 - conjugative metabolizing enzymes 337
 - for cytochrome P450 328
 - SARs 328, 329
 - 3D models 335, 336
 - 3D QSAR methods 340
 - enzyme induction 336, 337
 - of human hepatic microsomal intrinsic clearance 340
 - local *vs.* global 325, 326
 - machine learning 327, 333
 - models 325
 - MLR-based 326
 - models, classification 334, 335
 - molecular descriptors 324
 - multiple linear regression (MLR) 323
 - predictive ability 327
 - SAR 326
 - *in silico* 324
 - prediction 324
 - sulfotransferases 338, 339
 - training SAR 325
 - uridine diphosphate glucosyltransferase (UGT) 338
 - *in vitro* clearance 339, 340
 - QSAR prediction
 - experimental data/assays 376–378
 - phosphoglycoprotein (*P-gp*)-mediated disposition 376, 380, 385–388
 - substrate identification 378–380

- quantitative reverse transcription polymerase chain reaction (qRT-PCR) 473
- quantitative structure–activity relationship (QSAR), *see* QSAR models
- quantum mechanical (QM)
- calculations 37
 - tool 134
- quenching 9
- quinone reductases 9
- r**
- random forest (RF) 335, 380
- reactive nitrogen species (RNSs) 9
- reactive oxygen species (ROSs) 8, 9
- reactivity models 40, 41
- for CYP reactions 268
 - – combined carbon atom models 273
 - – comprehensive models 273, 274
 - – epoxidation of aromatic and double bonded carbon atoms 271, 272
 - – hydroxylation
 - – – aliphatic carbon atoms 268–270
 - – – aromatic and double bonded carbon atoms 271, 272
 - CypScore 41
 - SMARTCyp 40
 - software for 40, 41
 - StarDrop 40, 41
- receiver operating characteristic (ROC) curves 38, 312
- recombinant enzymes 232, 233, 238, 457, 458
- recursive partitioning (RP) 335, 380
- regioselectivity
- P450 Regioselectivity module of Percepta 42
 - RegioSelectivity (RS)-WebPredictor 42, 67, 281
- registration, evaluation, and authorization of chemicals (REACH) 323
- reliability index (RI) 42
- retinoid X receptor (RXR) 461
- reversed-phase (RP) chromatography 487, 494
- rhodamine-123 375
- rifampicin 365, 441, 461, 469, 470
- ritonavir 87, 88, 105, 106, 115, 122, 453, 459, 469, 470
- root mean square error (RMSE) 324
- rosiglitazone 235
- GSH adducts 235
 - *in vivo* liver toxicity 235
- RS-WebPredictor 42, 67, 68
- s**
- sandwich culture model 429
- SAR, *see* structure-activity relationship (SAR)
- Scutellaria baicalensis* 359
- shape-focused approaches 42, 43
- single-nucleotide polymorphisms (SNPs) 456
- site of metabolism (SoM) prediction 30, 38
- competition between different SoMs with regard to 267
 - Metabolism module of ADMET Predictor 42
 - methods for 31–36
 - software 38
 - SoM predictors 56, 66
 - structure-based predictions 243
- SMARTCyp approach 45, 67, 248
- for CYP isoforms 2D6 and 2C9 248
 - for descriptor calculation 42
 - software 40
- SMIRKS rules 267
- sodium taurocholate cotransporting polypeptide (NTCP) 373
- soft drugs 6
- software for predicting interactions of small molecules
- ADMET Predictor Metabolism module 47
 - ADMEWORKS Predictor 48
 - isoCyp 47
 - with metabolizing enzymes 46–48
 - MetaDrug 47
 - MetaPred 47
 - PASS 48
 - Percepta software package 46, 47
 - VirtualToxLab 48
 - WhichCyp 47
- software for predicting metabolites 43
- data mining and machine learning approaches 46
 - – Metaprint2D-React 46
 - knowledge-based systems 44, 45
 - – JChem Metabolizer 45
 - – META 44
 - – MetabolExpert 44
 - – MetaDrug 45
 - – Meteor 44, 45
 - – SyGMa 45
 - – TIMES 45
 - – UM-PPS 45
 - molecular interaction fields 46
 - – MetaSite 46
- software for predicting sites of metabolism 38

- data mining and machine learning approaches 41, 42
 - – Fast MEtabolizer (FAME) 42
 - – Metaprint2D 41
 - – P450 Regioselectivity module of Percepta 42
 - – RegioSelectivity (RS)-WebPredictor 42
 - docking 39, 40
 - – IDSite 40
 - knowledge-based systems 38, 39
 - – MEXAlert 39
 - – QikProp 39
 - molecular interaction fields 39
 - – MetaSite 39
 - reactivity models 40, 41
 - – CypScore 41
 - – SMARTCyp 40
 - – StarDrop 40
 - shape-focused approaches 42, 43
 - – ROCS 43
 - solid-phase extraction (SPE) 491
 - S*-oxidation 42
 - specificity (sp) 386
 - StarDrop software 40, 41
 - statins 441
 - statistical mechanics 180
 - steroids 77
 - structural variability 83, 97
 - CYP1A2 83–85
 - CYP2A6 85
 - CYP3A4 87, 88
 - CYP2C9 85, 86
 - CYP2D6 86
 - CYP2E1 87
 - structure-activity relationship (SAR) 39, 322
 - based on chemical bond energy 211
 - based on docking 211, 212
 - based on products 210, 211
 - – knowledge-based SAR 212
 - – SARs based on chemical bond energy 211
 - – SARs based on docking 211, 212
 - CYP inhibitor
 - – SAR, related to ionization state 330
 - – SAR, related to molecular size 331
 - 3D-QSAR modeling 15
 - GRID/GOLPE QSAR methodology 337
 - knowledge-based 212
 - PLS-based QSAR model 340
 - reaction rates 213
 - SAR of reaction rates 213
 - training SAR 325
 - structure-based methods 37
 - molecular docking (*see* molecular docking)
 - for predicting metabolism 30
 - for predicting sites and products of metabolism (*see* 6 Å Rule; protein flexibility)
 - structure-based prediction 40
 - structure–function relationships 77
 - structure–metabolism relationships (SMRs) 30
 - substrate and inhibitor pharmacophore models
 - cytochrome P450 enzymes 354
 - – CYP3A5 inhibitors 360
 - – CYP3A7 inhibitors 360
 - – CYP3A4 substrate pharmacophore model 359, 360
 - – CYP1A2, substrates/inhibitors 354, 355
 - – CYP2B6 substrates 355, 356
 - – CYP2C9 ligands 356, 357
 - – CYP2C19, substrates 357, 358
 - – CYP2D6 model 358, 359
 - interference with phase I metabolic enzymes 362, 363
 - UDP-glucuronosyltransferases (UGTs) 9, 29, 361, 402, 422
 - – UGT1A1 substrates 361
 - – UGT1A4 substrates 361
 - – UGT1A9 substrates 361, 362
 - – UGT2B7 substrates 362
 - substrate recognition sites (SRSs) 82, 83
 - substrate specificity profiles 83
 - sulfation 337, 400, 422, 490
 - sulfotransferases (SULTs) 9, 17, 29, 337, 338, 339, 422
 - sulfoxidation 10, 133
 - SuperCYP database 64
 - supernatant (S9) 446
 - superoxide dismutase (SOD) 9
 - Supersomes 424, 426, 428, 434
 - support vector machine (SVM) 67, 380
 - classification models 334
 - SyGMa (Systematic Generation of potential Metabolites) 34, 45, 297, 311
- t**
- tamoxifen 7, 105, 106
 - temazepam 6
 - terfenadine 444
 - testosterone 164, 203
 - hydroxylation 201
 - sites of oxidation by CYP3A4 212
 - tetrachlorodibenzo-*p*-dioxin (TCDD) 460

thermodynamic integration 185
 thin layer chromatography (TLC) 486
 time-dependent inhibition (TDI) 266
 time-of-flight (TOF) 238, 487, 488
 TIMES (Tissue Metabolism Simulator) 34,
 45, 301
 tissue microsomal systems 201
 TNO developed Intestinal Model
 (TIM-2) 421
 total free energy 249
 toxicity pathways 408
 toxicophores 9
 toxification 3, 7–9
 toxophores 9
 ToxTree software 267
 tramadol 7
 transactivation assays 465
 transcription factor activators 464
 – *in vitro* screening methods 464
 transferases 16
 transferase–transporter coupling 10
 transition state theory (TST) 183
 trapping assays 496
 trichloroacetic acid (TCA) 491
 troglitazone 105, 111, 112, 122, 234, 235
 trovofloxacin 405

u

UDP-glucuronosyltransferases 17, 444
 UGT1A1 enzyme 442, 446
UGT1A gene 473
 UM-BBD database 45, 69
 UM-PPS web server 45, 69
 uridine diphosphate glucosyltransferases
 (UGTs) 337

v

validation 30
 – assay validation
 – – analytics 434
 – – reference compounds, selection
 433, 434
 – *in vitro* model, theoretical steps 434,
 435
 – maximum unbiased validation (MUV)
 database 352
 – MetaSite 231

– model validation 312–314, 327
 van der Waals (vdW) interactions 185
 very low-density lipoprotein (VLDL) 437
 vitamin K epoxide reductase complex
 (VKORC1) 406
 VolSurf descriptors 380, 384, 388

w

warfarin 441
 – crystal structure 363
 – ligands 357
 water 254
 – computational studies 254
 – effect of crystallographic water molecule in
 CYP1A2 254
 – effect of water molecules
 – – on predicted docking poses 255
 – – – SoM predictions, effects sorted in
 classes 255
 – – and protein structures 256
 – entropic effect 254
 – x-ray structure of CYP1A2 254
 web-accessible databases 54
 web servers 53, 54, 71
 well-stirred model 432
 whole-cell hepatocyte assays 339
 Wikipedia 53
 WikiProjects 60
 World Wide Web 53

x

xenobiotics 104, 415, 417
 – classification of human CYPs based on 200
 – CYPs induction 336
 – definition 415
 – detoxification process 418
 – drug's clearance 441
 – harmful 367
 – metabolism 3, 30
 – – enzymes expression of 459, 460, 463
 – – factors influencing 18
 – – genes, mRNA expression of 471
 – – principal metabolic proteins 322
 – metabolite prediction 66
 – response elements (XREs) 460
 XMetDB database 266
 x-ray diffraction 206

